studies

454A AASLD ABSTRACTS HEPATOLOGY, October, 2015
486
Clinical Features and Treatment Modalities of Long-Term
Survivors with Advanced Hepatocellular Carcinoma: A
Single Institution Cohort Study
Kyung Hee Kim 1 , Joong-Won Park 1,2 , Bo Hyun Kim 1 , Chang-Min
Kim 1 , Byung Ho Nam 2 ; 1 Center for Liver Cancer, National cancer
center, Go yang si, Korea (the Democratic People’s Republic of);
2 Department of Cancer Control and Policy, Graduate School of
Cancer Science and Policy, National Cancer Center, Go yang si,
Korea (the Democratic People’s Republic of)
Background and Aim: The prognosis of patients with advanced
hepatocellular carcinoma (HCC) is poor despite systemic or
local treatments. We analyzed the characteristics of long-term
survivors (LTS) with advanced HCC to determine the prognostic
and treatment factors responsible for long-term survival. Methods:
Between January 2001 and December 2010, 543 patients
were first diagnosed as having modified International Union
Against Cancer (mUICC) stage IV HCC, with Child-Pugh (CP)
class A liver function at the National Cancer Center, Korea.
The authors retrospectively reviewed all medical records and
radiographs. Among the patients, we compared clinical features
and treatment modalities of the LTS group (survival > 24
months; n = 66) with those of the control (C) group (survival < 6
months; n = 333). Results: For 543 patients, the median overall
survival (OS) was 4.6 months (95% CI: 4.2-5.0): 37.7 months
(95% CI: 34.4-41.0) in the LTS group and 3.1 months (95%
CI: 2.9-3.3) in the C group. Compared to the C group, LTS
group patients were significantly more likely to be older and
to have non-hepatitis B virus etiology, lower tumor numbers,
smaller tumor size, nodular-type tumors, absence of portal vein
invasion, and better liver function. Ill-defined tumor type, portal
vein invasion and CP A6 proved to be independent prognostic
variables (p